MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
349.00
+0.23
+0.07%
Pre Market: 352.37 +3.37 +0.97% 05:12 03/31 EDT
OPEN
351.83
PREV CLOSE
348.77
HIGH
351.83
LOW
348.13
VOLUME
720
TURNOVER
511.89M
52 WEEK HIGH
391.29
52 WEEK LOW
253.48
MARKET CAP
188.13B
P/E (TTM)
24.53
1D
5D
1M
3M
1Y
5Y
1D
Top Stock Reports for Roche, AT&T & Amgen
NASDAQ · 13h ago
Merck oral PCSK9 enlicitide shows improved cholesterol lowering vs. non-statins
Seeking Alpha · 15h ago
Teva gains approval of biosimilar of Amgen's Prolia
Seeking Alpha · 18h ago
Weekly Report: what happened at AMGN last week (0323-0327)?
Weekly Report · 23h ago
Reported Saturday, Amgen's Repatha Reduces 3-P MACE Risk By 31% In VESALIUS-CV Subgroup Analysis Of 3,655 High-Risk Diabetic Patients Without Prior Heart Attack Or Stroke
Benzinga · 1d ago
Amgen announces data on Repatha from Phase 3 Vesalius-CV trial
TipRanks · 1d ago
Amgen’s Repatha Data Reinforces Cardiovascular Franchise And Valuation Debate
Simply Wall St · 2d ago
Amgen says Repatha cuts first major cardiovascular events 31% in VESALIUS-CV subgroup
Reuters · 2d ago
More
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.

Webull offers Amgen Inc stock information, including NASDAQ: AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.